Flavoxate Hydrochloride CAS 3717-88-2

Product Description:

Product Name: Flavoxate hydrochloride CAS NO: 3717-88-2

Synonyms:

2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,hydrochloride;

1-piperidineethanol,3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylate,h;

3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylicaci2-piperidinoethyl;

Chemical & Physical Properties:

Appearance: White solid

Assay :≥99.0%

Density: 1.203g/cm3

Boiling Point: 564.1℃ at 760 mmHg

Melting Point: 232-234℃

Flash Point: 294.9℃

Safety Information:

RTECS: DJ2450000

Safety Statement: S26

HS Code: 2934999090

Risk Statements: R22; R36/37/38

Hazard Code: Xn

Hazard Declaration: H302; H315; H319; H335

Symbol: GHS07

Signal Word: Warning

Caution Statement: P261; P305 + P351 + P338

Smooth muscle relaxant. Used as antispasmodic; in treatment of urinary incontinence.

Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.Target: mAChRFlavoxate displaces [3H]nitrendipine on the Ca2+ channels binding sites with IC50 of 254 μM. Flavoxate (>10 μM) suppresses carbachol-induced contractions in isolated rat detrusor strips with pD value of 4.55. Flavoxate (>10 μM) suppresses Ca2+-induced contractions in isolated rat detrusor strips with pIC50 value of 4.92. Flavoxate (0.01 μM ?10 μM) inhibits CAMP formation in a concentration-dependent manner in membranes from the rat striatum and cerebral cortex, an action which is completely abolished by pretreating the membranes with pertussis toxin (PTX) [3].Flavoxate (10mg/kg) suppresses both the an initial, rapidly rising phasic contraction (phase 1) and the tonic contraction (phase 2) contractions to the same extent in rats. Flavoxate (10mg/kg) abolishes the bladder contractions without causing any change in the amplitude of the contractions in rats. Flavoxate (3 mg/kg) abolishes the efferent neural activity and the associated bladder contractions for about 10 minutes without changing the baseline vesical pressure in rats. ICV-injected (50 to 200 μg/rat) or IT-injected (100 to 200 μg/rat) Flavoxate abolishes rhythmic bladder contractions during and after injection for five to 15 minutes in a dose-dependent manner in rats. Flavoxate (3 mg/kg, i.v.) abolishes rhythmic bladder contractions and the maximal intervals of voiding contractions is 7.20 min.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.